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ABSTRACT
Exposure to the ubiquitous environmental contaminant trichloroethylene (TCE) is associated with cancer and non-cancer
toxicity in both humans and rodents. Peroxisome proliferator-activated receptor-alpha (PPARa) is thought to be playing a
role in liver toxicity in rodents through activation of the receptor by the TCE metabolite trichloroacetic acid (TCA). However,
most studies using genetically altered mice have not assessed the potential for PPARa to alter TCE toxicokinetics, which
may lead to differences in TCA internal doses and hence confound inferences as to the role of PPARa in TCE toxicity. To
address this gap, male and female wild type (129S1/SvImJ), Ppara-null, and humanized PPARa (hPPARa) mice were exposed
intragastrically to 400 mg/kg TCE in single-dose (2, 5 and 12 h) and repeat-dose (5 days/week, 4 weeks) studies. Interestingly,
following either a single- or repeat-dose exposure to TCE, levels of TCA in liver and kidney were lower in Ppara-null and
hPPARa mice as compared with those in wild type mice. Levels of trichloroethanol (TCOH) were similar in all strains. TCE-
exposed male mice consistently had higher levels of TCA and TCOH in all tissues compared with females. Additionally, in
both single- and repeat-dose studies, a similar degree of induction of PPARa-responsive genes was observed in liver and
kidney of hPPARa and wild type mice, despite the difference in hepatic and renal TCA levels. Additional sex- and strain-
dependent effects were observed in the liver, including hepatocyte proliferation and oxidative stress, which were not
dependent on TCA or TCOH levels. These data demonstrate that PPARa status affects the levels of the putative PPARa
agonist TCA following TCE exposure. Therefore, interpretations of studies using Ppara-null and hPPARa mice need to
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consider the potential contribution of genotype-dependent toxicokinetics to observed differences in toxicity, rather than
attributing such differences only to receptor-mediated toxicodynamic effects.
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Trichloroethylene (TCE) is classified as a human carcinogen
based on convincing evidence for a positive association with (1)
renal-cell carcinoma in humans and (2) tumors of multiple sites
in mice and rats of both sexes (Guha et al., 2012). The epidemio-
logical evidence for the association between TCE exposure and
liver cancer in humans is limited, even though liver is a well-
established target organ in mice. Activation of peroxisome pro-
liferator-activated receptor alpha (PPARa) is one of the mecha-
nisms thought to be involved in the pathogenesis of liver cancer
in mice exposed to TCE. In humans, the role of PPARa remains
as a contentious issue in hazard assessment of TCE and other
agents (Corton et al., 2014; Keshava and Caldwell, 2006).
The absence of functional PPARa completely abolished the
hepatocarcinogenic response from the prototypical and highly
potent ligand WY-14 643 in the mouse (Peters et al., 1997). Mice
expressing human PPARa (hPPARa) also have diminished hepa-
totoxic or hepatocarcinogenic responses when exposed to the
peroxisome proliferators fenofibrate (Cheung et al., 2004) or WY-
14 643 (Morimura et al., 2006). A number of hypotheses have
been proposed to link PPARa and liver carcinogenesis through
alterations in cell proliferation and apoptosis (Peters, 2008;
Peters et al., 2012). At the same time, in a mouse model of con-
stitutive activation of this nuclear receptor in liver, cell prolifer-
ation but not liver cancer were reported, which suggests that
ligand activation and recruitment of co-effector proteins may
also play an important role (Yang et al., 2007). Inter-individual
and inter-species differences in genomic sequence, expression
patterns and signaling cascades of PPARa have been reported,
further compounding the challenge of assessing the relative
role of this mechanism in carcinogenesis (Rusyn and Corton,
2012). Additional mechanisms may also be operational in the
pathogenesis of environmental chemicals that are weak or
nonselective agonists of PPARa (Ito et al., 2012; Ren et al., 2010;
Wood et al., 2014).
TCE is a relatively weak activator of either human or murine
PPARa, but TCE metabolites tri- and di-chloro acetic acids (TCA
and DCA) were found to be more potent activators (Maloney
and Waxman, 1999; Zhou and Waxman, 1998). TCE-induced
peroxisome proliferation response in mouse liver and kidney is
thought to be mediated exclusively by TCA and DCA (Corton,
2008; Rusyn et al., 2014). Moreover; TCE metabolism to TCA and
DCA is not thought to involve PPARa-inducible cytochrome P450
enzymes (Lash et al., 2014). Several studies observed abrogated
toxic effects (eg, increased peroxisomal volume and peroxi-
somal enzyme activity) of TCE in Ppara-null mice (Laughter
et al., 2004; Nakajima et al., 2000; Ramdhan et al., 2010). In addi-
tion, in mouse exposed to TCE, strain-specific tissue levels of
TCA and DCA have been shown to be highly correlated with
PPARa activation in liver (Yoo et al., 2015a) and kidney (Yoo et al.,
2015b).
Taken together, these studies suggest a simple toxicoki-
netic-toxicodynamic adverse outcome pathway whereby: (1)
TCE is metabolized to TCA and DCA in the liver; (2) these metab-
olites activate PPARa in the liver (where they are formed in situ)
and kidney (where they are transported for urinary excretion);
and (3) activation of PPARa leads to a cascade of hepatocellular
responses that may contribute to TCE-associated
hepatocarcinogenesis in mice. However, a study of TCE inhala-
tion in wild type, Ppara-null, and hPPARa mice (Ramdhan et al.,
2010) showed genotype-dependent differences in levels of uri-
nary TCA and trichloroethanol (TCOH), suggesting that PPARa
status may actually affect TCE toxicokinetics. This in turn may
affect the interpretation of previous studies which exposed
Ppara-null and hPPARa mice to TCE, since differences in re-
sponses may not be due solely to differences in activation of
PPARa (or lack thereof) but also in the production of metabolites.
To test the hypothesis that PPARa status affects TCE toxicoki-
netics, we measured TCE and its metabolites in serum, liver,
and kidney in wild type, Ppara-null, and hPPARa mice exposed
to TCE acutely and sub-chronically by oral gavage. Additionally,
to assess the relative contributions of toxicokinetics or toxico-
dynamics to TCE-induced hepatic and renal toxicity, we mea-
sured hepatic and renal levels of PPARa-responsive genes as
well as biochemical markers of toxicity. Our results demon-
strate that PPARa status affects TCE toxicokinetics in the liver
and kidney. Such alternations in toxicokinetics may contribute
to genotype-dependent differences in toxic responses in mouse
liver and kidney.
MATERIALS AND METHODS
Animals and treatments.. Male and female mice from 3 different
genotypes were used. Wild type (129S1/SvImJ) and Ppara-null
(129S4/SvJae-Pparatm1Gonz/J) mice of 9–10 weeks of age were pur-
chased from the Jackson Laboratory (Bar Harbor, Maine), and
humanized-PPARa (hPPARa) mice on an Sv/129 genetic back-
ground (Cheung et al., 2004) were provided by Dr Frank Gonzalez
(Laboratory of Metabolism, National Cancer Institute). All mice
were housed in polycarbonate cages on Sani-Chips (P.J. Murphy
Forest Products Corp., Montville, New Jersey) irradiated hard-
wood bedding. Animals were fed an NTP-2000 (Zeigler Brothers,
Inc., Gardners, Pennsylvania) wafer diet and water ad libitum on
a 12-h light-dark cycle. All studies were approved by the UNC
Institutional Animal Care and Use Committee.
Two study designs were utilized in this work. First, we per-
formed a sub-chronic study where TCE (400 mg/kg/day, in 5%
Alkamuls EL-620 in saline) was administered by gavage to male
and female mice from the 3 different genotypes for 4 weeks (5
days/week). Mice were also given drinking water containing
0.2 g/l of 5-bromo-20-deoxyuridine (BrdU) for 72 h prior to sacri-
fice. Blood, liver, kidney, and a section of a duodenum were col-
lected 5 h after the last TCE treatment in order to evaluate levels
of TCE metabolites in mouse tissues and cell proliferation in the
liver and kidney. This time point was selected based on a toxi-
cokinetics study of TCE metabolism in the mouse to represent a
time window when all metabolites are close to their peak levels
(Kim et al., 2009b). Second, we conducted a toxicokinetic study
where wild type, Ppara-null, and hPPARa mice received a single
dose (400 mg/kg) of TCE in 5% Alkamuls EL-620 in saline by gav-
age and sacrificed 2, 5, and 12 h after TCE treatment followed by
the collection of liver, kidney, and blood. Blood was drawn from
vena cava and centrifuged to prepare serum using Z-gel tubes
(Sarstedt, Germany) according to the manufacturer’s
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instructions. In both studies, body and organ weights were
recorded. Liver, kidney, and duodenum sections were fixed in
neutral buffered formalin for 24 h, and the remainder of the
liver and kidney tissues were frozen in liquid nitrogen. All
serum and tissue samples were stored at 80C until analyzed.
Quantification of TCE.. Prior to extraction, liver (100 mg) and kid-
ney (30 mg) samples were homogenized with 2 volumes of
deionized water (w/v) using a finger pestle. Tissue homogenate
(200 ll) were transferred to autosampler vials containing 200 ll
of ammonium sulfate solution, and then 1 ll of internal stand-
ard (TCE-deuterated) were added using a microsyringe. The
vials were vortexed for 30 s and placed into the autosampler for
analysis. The analyses were carried out on an Agilent 7890 gas
chromatograph (GC) coupled with a 5975C mass selective detec-
tor. The GC was equipped with a 0.75 mm i.d. Solid Phase
Microextraction (SPME) liner. Separation of the analytes was
obtained on DB-5MS column (Phenomenex, 30 m 0.25 mm i.d.,
0.25 lm film thickness) using helium as a carrier gas (flow rate,
1 ml/min). The GC injection port and interface transfer line were
maintained at 200 and 280C, respectively. During the fiber
desorption process, the splitless mode of injection was oper-
ated. After 2 min, the split vent valve opened to sweep any
residual vapors from the liner. The oven temperature was
initially held at 35C for 3 min, and then increased to 70C at
10C/min. The mass spectrometer was operated positive
electron ionization mode with electron energy of 71 eV.
Quantitation of TCE was performed using selected-ion monitor-
ing mode by measuring the signal for m/z 130 (131 for TCE-d).
GC-SPME was performed using a 100 lm polydimethylsiloxane
fiber mounted on a Combi-Pal system autosampler. Fibers were
conditioned at 200C for 30 min prior to use. Sample vials were
preheated in the agitator for 5 min before analysis, and the
SPME fiber was then exposed to the headspace by piercing the
septum with the needle of the fiber assembly. After extraction
for 15 min at 30C under agitation, the fiber was withdrawn into
the needle and immediately desorbed at 200C for 2 min into
the GC injection port.
Quantification of TCE metabolites. The levels of TCA in liver and
kidney tissues were determined using HPLC-ESI-MS/MS as
detailed elsewhere (Kim et al., 2009a) with slight modifications
as follows. Two milliliter Eppendorf Safe Lock Tubes containing
one stainless steel ball each with 300 ll of chloroform and 60 ll
of water were incubated on dry ice for 10 min in a cooling block.
Liver (100 mg) or kidney (50 mg) tissue was then incised from
frozen tissue samples and placed into each of these tubes.
Internal standard (trifluoroacetic acid, 40 nmol/ml) was added
to make 100 ll of final aqueous volume. The tubes were then
homogenized at 30 Hz for 3 min using TissueLyser (Qiagen,
Valencia, California). After homogenization, the tubes were cen-
trifuged at 14 000 g for 30 min at 4C. Aqueous liver or kidney
extract was transferred to a centrifugal filter unit (Amicon Ultra
0.5, Millipore, Masschusetts) and centrifuged at 14 000g for
60 min at 4C. After centrifugation, the filtrate was transferred
to a glass vial containing 300 ll vial insert and was stored at
80C until injection to HPLC-ESI-MS/MS with an Aquity UPLC
system (Waters, Milford, Masschusetts) coupled to a TSQ
Quantum Ultra triple-quadrupole mass analyzer (Thermo
Fisher Scientific, Waltham, Masschusetts) using a heat-assisted
electrospray ionization source. A YMC ODS-AQ analytic column
(150 2 mm, 3 mm; Waters, Milford, Masschusetts) was used in
an isocratic mode with mobile phase (1 mM ammonium citrate
in the mixture of 70% acetonitrile and 30% water). The lower
limit of quantification (LLOQ) in this study for TCA was 8 nmol/g
in liver and 15 nmol/g in kidney.
The method of Song and Ho (2003) was used for quantitation
of total TCOH (free TCOH plus TCOH-glucuronide) in liver, kid-
ney, and serum, with minor modifications. Briefly, liver (30 mg),
kidney (30 mg), or serum (50 ml) was homogenized in 500 ll of
sodium acetate buffer (pH 4.6) with 1000 units of b-glucuroni-
dase (Sigma [G0751], St. Louis, Missouri) using Tissuelyser
(Qiagen) for 1 min, followed by overnight incubation at 37C.
After centrifugation at 14 000g for 5 min, the supernatant was
transferred to a new tube, then mixed with 20 ml internal stand-
ard (DCA, 10 mM in methanol) and 550 ll of water/0.1 M sulfuric
acid/methanol (6:5:1). The mixture was heated at 70C for
20 min. After cooling to room temperature, 2.5 ml hexane was
added, the mixture vortexed for 10 min and centrifuged at
2500g for 2 min. The upper layer was concentrated under a
stream of N2 to <20 ll and used for GC-MS analysis as detailed
in (Song and Ho, 2003). The LLOQ was 5 nmol/g in liver.
Determination of triglyceride content in liver.. Triglycerides were
extracted by homogenizing 20 mg of frozen liver tissue in 500 ml
of isopropyl alcohol, and 4 ml of the extract was used in subse-
quent analysis. The level of triglycerides was determined by
using L-type Triglyceride-M Assay Kit (Wako Chemicals,
Richmond, Virginia) according to the manufacturer’s
instructions.
Quantification of glutathione, cysteine, and nicotinamide adenine dinu-
cleotide phosphate redox status.. The concentrations of free
reduced (GSH) and oxidized glutathione (GSSG) and cellular
methylation biomarkers, S-adenosyl-L-methionine (SAM) and
S-adenosyl-L-homocysteine (SAH) were determined as meas-
ures of redox/metabolic status in liver and kidney by using the
high performance liquid chromatography (HPLC) with colori-
metric electrochemical detection (HPLC-ED) system (MCM, Inc.,
Tokyo, Japan). The methodological details for the detection of
GSH and GSSG (Melnyk et al., 1999), SAM and SAH (Melnyk et al.,
2000) by HPLC have been described previously. NADPH/nicotina-
mide adenine dinucleotide phosphate (NADP)þ ratio in liver
was measured using a NADP/NADPH Quantification Kit (Sigma,
St. Louis, Missouri) according to the manufacturer’s
instructions.
Gene Expression Analysis by Real-Time PCR
Total RNA was isolated from liver and kidney samples using an
RNeasy kit (Qiagen) according to the manufacturer’s instructions.
RNA concentration and quality were determined using an ND-
1000 spectrophotometer (Nanodrop Technologies, Wilmington,
Delaware) and Agilent 2000 Bioanalyser, respectively. Total RNA
was reverse transcribed using random primers and the high
capacity complementary DNA archive kit (Applied Biosystems,
Foster City, California) according to the manufacturer’s protocol.
The following gene expression assays (Applied Biosystems) were
used for quantitative real-time PCR: peroxisome proliferator–
activated receptor alpha (Ppara, Mm00440939_m1); palmitoyl acyl-
Coenzyme A oxidase 1 (Acox1, Mm01246831_m1); cytochrome
P450, family 4, subfamily a, polypeptide 10 (Cyp4a10, Mm011
88913_g1); and beta glucuronidase (Gusb, Mm00446953_m1).
Reactions were performed in a 96-well plate, and all samples
were plated in duplicate using LightCycler 480 instrument (Roche
Applied Science, Indianapolis, Indiana). The cycle threshold (Ct)
for each sample was determined from the linear region of the
amplification plot. The DCt values for all genes relative to the con-
trol gene Gusb were determined. The DDCt were calculated using
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treated group means relative to strain-matched control group
means. Fold change data were calculated from the 2^-DDCt values
(Livak and Schmittgen, 2001).
Determination of hepatocyte and proximal tubule cell proliferation..
Deparaffinized and rehydrated liver and kidney sections from
the sub-chronic study were immersed in 4 N HCl and subse-
quently pepsin solution (Dako, Carpinteria, California) for anti-
gen retrieval and then incubated in peroxidase blocking reagent
(Dako). Dako EnVision System HRP kit was used for the detec-
tion of BrdU-incorporated nuclei (monoclonal anti-bromodeox-
yuridine antibody, Dako, 1:200 dilution). Data for liver tissues
were presented as a fraction of BrdU staining-positive nuclei in
the centrilobular region (no fewer than 1000 nuclei counted per
liver section). Data for kidney tissues were presented as a frac-
tion of BrdU staining-positive nuclei in the tubular epithelium
of the renal cortex (no fewer than 1000 nuclei counted per kid-
ney section).
Determination of KIM-1 expression in kidney.. Detection of KIM-1
was accomplished by modifying a published method
(Humphreys et al., 2011). Formalin-fixed and paraffin-embedded
kidney sections were deparaffinized and rehydrated. Antigens
were retrieved by 4N HCl and pepsin solution (Dako) afterward.
After peroxidase blocking, immunohistochemical detection was
conducted using Dako Liquid DAB Substrate Chromogen System
with primary anti KIM-1 antibody (2 mg/ml in PBS) (R&D
Systems, Minneapolis, Minnesota) and secondary goat IgG HRP-
conjugated Antibody (1:100 in PBS) (R&D Systems). The propor-
tion of positive-stained proximal tubules in outer medulla was
determined under light microscopy. Data were presented as a
fraction of proximal renal tubules staining positive for KIM-1
(no fewer than 200 proximal renal tubules counted per kidney
section).
Statistical analysis.. Toxicokinetic data from the single dose study
were fit using nonlinear 2-phase exponential association and
statistical analysis was performed via repeated measures (strain
and time) ANOVA. For all other end points, ANOVA with
Newman-Keul’s post hoc test was performed. For all statistical
tests, a p-value of <.05 was required for statistical significance.
RESULTS
Concentration-Time Profiles of TCE Metabolism Through Oxidative
Pathway in Wild Type, Ppara-Null and hPPARa Mice
First, levels of TCE were measured in liver and kidney of male
and female wild type, Ppara-null and hPPARa mice at 2, 5, or 12 h
following a single intragastric dose of 400 mg/kg. Relatively low,
but detectable, levels of TCE (Fig. 1) were found in both tissues
and sexes across strains, consistent with rapid metabolism
(Lash et al., 2014). Generally, in both tissues, levels of TCE were
highest (5–15 nmol/g tissue) at 2–5 h postdosing; TCE was essen-
tially cleared from these tissues 12 h after administration. In
liver of male mice of all 3 strains, no differences in TCE concen-
tration-time profiles were observed; however, in kidney of male
Ppara-null mice we found a significantly lower amount of TCE
at 2 h after dosing, as compared with wild type mice. In female
mice, liver levels of TCE in wild type and Ppara-null mice were
greater than in hPPARa mice at 2 h; at 12 h, levels of TCE in liver
of wild type mice were also different from those in Ppara-null
FIG. 1. Kinetics of TCE in (A) liver and (B) kidney of male mice, and in (C) liver and (D) kidney of female mice following a single dose of TCE (400 mg/kg i.g.). The data
shown are mean 6 SD, n¼3 animals per group. Symbols indicate significant (p< .05) differences between the values at each time point between strains as follows: wild
type versus Ppara-null (*), wild type versus hPPARa (#), and Ppara-null versus hPPARa ($) mice.
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mice. No inter-strain differences in concentration-time profiles
of TCE in kidney were observed in female mice.
Second, we evaluated concentration-time profiles of TCOH.
Of the 3 tissues examined, the highest levels of TCOH were
found in serum in both male and female mice of all strains
(Fig. 2). TCOH levels in liver and kidney were 40- to 100-fold
higher than TCE levels in these tissues, respectively. TCOH lev-
els in serum were 2- to 5-fold higher than those in liver and kid-
ney. There were sex differences in concentration-time profiles
of TCOH such that in female mice, the amounts of TCOH were
about one half of those in male mice. No strain differences were
observed in the levels of TCOH in liver, kidney, or serum, except
for male hPPARa mice at 5 h after dosing.
Third, concentration-time profiles of TCA, another abundant
oxidative metabolite of TCE, were assessed. Differences in TCA
levels in liver and kidney were found between sexes and strains
(Fig. 3). In male wild type mice, levels of TCA in liver were signif-
icantly greater than those in other strains. In kidney of male
mice, TCA levels in Ppara-null mice were significantly different
from those in wild type at all time points examined, and those
in hPPARa mice at 2 and 5 h. No difference in concentration-
time profiles in serum of male mice was observed among 3
strains. In females, the levels of TCA were about 2- to 4-fold
lower than in male mice. Similar to the findings in male mice,
levels of TCA in liver of wild type mice were significantly greater
than those in other strains.
Levels of TCE Metabolites Through Oxidative Pathway in Wild Type,
Ppara-Null and hPPARa Mice Following Subchronic (4 Weeks)
Treatment
To determine the effect of repeat administration of TCE on
metabolite profiles through oxidative pathway in multiple tar-
get tissues, male and female mice of wild type, Ppara-null and
hPPARa strains were dosed with 400 mg TCE/kg (i.g.) for 5 days/
week for 4 weeks. Liver, kidney, and serum were collected 5 h
after the final dose of TCE to enable comparisons with concen-
tration-time profiles conducted following a single TCE dose.
Following sub-chronic exposure, TCE levels in liver and kidney
(Fig. 4A and B) were 2- to 5-fold lower than those after a single
dose (Fig. 1) and were not different among sexes or strains.
However, levels of TCOH and TCA after sub-chronic exposure to
TCE (Fig. 4C–H) were consistent with those after acute TCE treat-
ment (Figs. 2 and 3, respectively), and their levels in male mice
were considerably higher than in female mice. Overall, levels of
TCOH were highest in serum, followed by kidney, then liver; lev-
els of TCOH were 30-fold higher in serum and 10-fold higher in
FIG. 2. Kinetics of TCOH in (A) liver, (B) kidney, and (C) serum of male mice, and in (D) liver, (E) kidney, and (F) serum of female mice following a single dose of TCE
(400 mg/kg i.g.). The data shown are mean 6 SD, n¼3 animals per group. No significant differences between groups were observed.
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kidney compared with levels of TCA in these tissues, but hep-
atic levels of these 2 metabolites were similar. Of all compounds
measured, the only significant differences were observed
among strains in liver levels of TCA, whereby the greatest
amounts of TCA were found in wild type mice of both sexes
(Fig. 4F).
We also compared strain- and sex-specific differences in oxi-
dative metabolism of TCE (ie, levels of TCOH and TCA in 3 tis-
sues examined) in the single dose study and a sub-chronic
study (Fig. 5). To enable this comparison, we calculated the total
amount of oxidative metabolites formed (in serum, liver, and
kidney) from TCE at each time point. There was no effect of
repeat TCE exposure on oxidative metabolite levels. Total level
of oxidative TCE metabolites was about 3-fold lower in females
compared with males in all 3 strains. Even though levels of TCA
in liver of wild type mice were different from those in Ppara-null
and hPPARa mice (Figs. 3 and 4F–H), when total oxidative metab-
olism of TCE is considered, no significant strain differences
were evident. However, the lack of differences in total oxidative
metabolite levels is due to dominating effect of TCOH which
was not different among strains (Figs. 2 and 4C–E). This is illus-
trated by the significant differences in ratios of TCA to TCOH
(Fig. 5E and F).
Strain (Wild Type, Ppara-Null, and hPPARa Mice)- and Sex-Specific
Effects of TCE on Liver and Kidney Toxicity
Because of the longer duration of TCE exposure (4 weeks) in a
sub-chronic study, as compared with an acute study (12 h),
most toxicity phenotypes were evaluated in the liver and kidney
tissues from the sub-chronic study. In liver, we examined liver
to body weight ratios, cell proliferation index, triglyceride levels,
levels of glutathione, s-adenosyl methionine and homocysteine,
NADPH/NADPþ ratios, and liver histology (Supplementary Figs.
S1 and S2). The most notable findings were a significant
increase in liver/body weight ratios of male wild type and Ppara-
null mice treated with TCE (Supplementary Fig. S1A) and an
associated decrease in GSH/GSSG ratio indicative of oxidative
stress (Supplementary Fig. S1D). In addition, in male wild type
mice exposed to TCE, liver triglycerides and NADP/NADPþ ratio
were significantly higher (Supplementary Fig. S1C and S1F).
Histopathological assessment revealed slight centrilobular
necrosis in male wild type mice treated with TCE for 4 weeks
(Supplementary Fig. 2). In addition, hepatic steatosis was evi-
dent in vehicle-treated Ppara-null mice, an effect that was
diminished upon exposure to TCE for 4 weeks. In the kidney, no
notable effects of TCE or strain-/sex-differences were found
(Supplementary Fig. S3).
FIG. 3. Kinetics of TCA in (A) liver, (B) kidney, and (C) serum of male mice, and in (D) liver, (E) kidney, and (F) serum of female mice following a single dose of TCE
(400 mg/kg i.g.). The data shown are mean 6 SD, n¼ 3 animals per group. Symbols indicate significant (p< .05) differences between the values at each time point
between strains as follows: wild type versus Ppara-null (*), and wild type versus hPPARa (#) mice.
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Next, we examined whether liver levels of Cyp2e1, a major
putative enzyme responsible for the oxidative metabolism of
TCE, vary across wild type, Ppara-null and hPPARa mice, or are
affected by sub-chronic treatment with TCE. Protein levels of
Cyp2e1 were measured in the livers of animals treated with
400 mg/kg TCE for 4 weeks and we found no strain-, sex-, or
treatment-associated differences (Fig. 6). However, TCE treat-
ment resulted in a significant increase in liver and kidney
expression of the PPARa-responsive genes Cyp4a10 (Fig. 7) and
Acox1 (Supplementary Fig. S4) in both wild type and hPPARa
mice. Induction of Cyp4a10 was most pronounced and of similar
magnitude (following either acute or sub-chronic treatment) in
male wild type and hPPARa, but not Ppara-null mice, albeit liver
induction was much greater than that in the kidney. In females,
these responses were muted with respect to the magnitude of
the effect, but the patterns of response were very similar (ie, ele-
vated in the wild type and hPPARa, but not Ppara-null mice) to
those in male mice. Effects on expression of Acox1 were similar
(Supplementary Fig. S4), but not identical. For instance, induc-
tion of Acox1 was only observed in wild type male liver and
female liver and kidney following a single dose of TCE.
Following sub-chronic exposure to TCE, Acox1 induction was
observed only in wild type and hPPARa mouse liver.
DISCUSSION
Association between exposure to TCE and PPARa signaling in
the liver of rodents is well-established (Corton et al., 2014;
Klaunig et al., 2003; Rusyn et al., 2014). Indeed, TCE oxidative
pathway metabolites, TCA and DCA, are capable of activating
mouse PPARa as evidenced by in vitro receptor activation assays
(Issemann and Green, 1990; Zhou and Waxman, 1998) and an
in vivo mouse study (Laughter et al., 2004). Likewise, an in vitro
transactivation study has demonstrated that human PPARa is
activated by either TCA or DCA, while TCE is relatively inactive
(Maloney and Waxman, 1999).
The importance of PPARa in TCE-induced hepatotoxicity was
previously examined in Ppara-null (Laughter et al., 2004;
Nakajima et al., 2000) and hPPARa mice (Ramdhan et al., 2010).
These studies consistently found that PPARa-mediated signal-
ing and morphological events, such as induction of peroxisomal
and other genes, were affected by TCE in wild type and hPPARa
mice, but not in Ppara-null mice. Our recent studies that exam-
ined the linkages between TCE metabolism and toxic effects in
liver and kidney in a multi-strain mouse population model (Yoo
et al., 2015a,b) found a significant positive correlation between
levels of TCA and induction of PPARa-responsive genes. These
and other studies conform to the simple hypothesis that differ-
ences in hepatotoxic responses across wild type, hPPARa mice,
and Ppara-null mice exposed to TCE are due to differences in
activation PPARa (or lack thereof) by TCE metabolites. However,
most studies of TCE effects in genetically-modified PPARa
mouse models did not examine the metabolism of TCE. Only
Ramdhan et al. (2010) reported that urinary levels of TCA were
significantly lower in Ppara-null as compared with wild type
mice. This suggests that diminished toxicity of TCE in hPPARa
mice and Ppara-null mice may be due, at least in part, to a lower
internal dose of the active metabolite TCA, and not solely due to
diminished receptor-related responses.
This study extends the findings of Ramdhan et al. (2010) to
include tissue-specific levels of TCE metabolites, elucidates the
potential role of PPARa in the relationship between
FIG. 4. Levels of TCE and its metabolites 5 h following the final dose of 400 mg/kg/d (i.g.) for 4 wk. Levels of TCE in (A) liver and (B) kidney. Levels of TCOH in (C) liver, (D)
kidney, and (E) serum. Levels of TCA in (F) liver, (G) kidney, and (H) serum following a single dose of TCE (400 mg/kg i.g.). Box and whisker plots are shown (þ, mean;
line, median; box, inter-quartile range; whiskers, min to max). When box is shown, 4 animals per group were available. Otherwise, there were 3 animals per group.
Symbols indicate significant (p< .05) differences as compared with wild type (*) or Ppara-null (¶) mice.
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toxicokinetics and toxicodynamics of TCE in mice, and specifi-
cally highlights the role of PPARa in metabolism of TCE. Our cur-
rent findings in orally treated mice are similar to those of
Ramdhan et al. (2010) who performed inhalation exposure to TCE,
in that we observed differences in TCE metabolism to TCA, but
not TCOH, among wild type, Ppara-null, and hPPARa mice.
Because our study used a different route of exposure and exam-
ined different durations of exposure and multiple tissues, this
consistency increases the confidence in our results. Together
these 2 studies conclusively show that PPARa status does play a
role in TCE metabolism. However, our study also found a consis-
tent (with respect to time, sex, and tissue) difference in TCA lev-
els between wild type and hPPARa mice, an effect not observed in
urinary TCA levels after TCE inhalation (Ramdhan et al., 2010).
Additionally, we found that wild type mice have higher lev-
els of TCA in their livers and kidneys, as compared with Ppara-
null and hPPARa mice. This suggests that PPARa may contribute
to the cellular metabolic capacity of TCE through oxidative
pathways. Formation of TCA and other oxidative metabolites is
thought to occur primarily through CYP2E1 (Lash et al., 2014;
Nakajima et al., 1992). The role of Cyp2e1 in TCE metabolism
was directly challenged in Cyp2e1-null mouse studies (Kim and
Ghanayem, 2006; Ramdhan et al., 2008). However, no differences
in levels of Cyp2e1 were observed in this study or in Ramdhan
et al. (2010). It was reported that TCE metabolism to TCA and
TCOH is 2- to 4-fold lower in Cyp2e1-null mice, as compared
with wild type animals, but is not completely abrogated. This
suggests that other P450 enzymes, such as mouse Cyp1a1/2
(Nakajima et al., 1993) and Cyp2f2 (Forkert et al., 2005), may also
play a role in TCE metabolism.
FIG. 5. Amount of TCE metabolized through oxidative pathways to TCA and TCOH from single- and repeat-dose studies following a 400 mg/kg (i.g.) dose. Top row shows
data from male mice, middle row shows data from female mice. Panels A, B, D, and E display total (liver, kidney, and serum) amounts of TCA (shaded areas) and TCOH
(white areas) formed at different time points in the single-dose study (A and B) and at 5 h after dosing in a repeat-dose study (panels D and E). The data for 3 mouse
strains are grouped as indicated in the x-axis legend. Panels C and F show the ratio of total TCA to TCOH formed at each time point and strain (as indicated by the
insets) in male (C) and female (F) mice. Data are mean 6 SD, n¼3/group. Symbols indicate significant (p< .05) differences as compared with wild type (*) or Ppara-null
(¶) mice.
FIG. 6. Protein levels of CYP2E1 in mice treated with 400 mg/kg (i.g.) TCE for 4
weeks. Protein expression was normalized to vehicle-treated group of the same
sex and strain. No strain- or sex-dependent differences were observed in basal
protein levels. Box and whisker plots are shown (þ, mean; line, median; box,
inter-quartile range; whiskers, min to max). When box is shown, 4 animals per
group were available. Otherwise, there were 3 animals per group. There were no
significant differences among groups.
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TCE also undergoes metabolism via conjugative pathways,
particularly with GSH, which are mediated by glutathione
s-transferases (Rusyn et al. 2014). Although TCE-GSH conjugates
have not been examined with respect to their potential binding
to PPARa, they are very low abundance metabolites (4–5 orders
of magnitude lower than levels of TCA) (Kim et al., 2009b; Yoo
et al., 2015a,b) and are thus not likely contributing to TCE-associ-
ated PPARa activation. It is also possible that modulating basal
PPARa levels increases the flux of TCA from the tissues to the
excreta, which would explain the decreased TCA levels in Ppara-
null and hPPARa mice; however, the effect would have to be
male-specific. Thus, the mechanism of how PPARa status may
alter the metabolism of TCE remains unclear and further exami-
nation is warranted.
It is interesting, however, that despite major differences in
TCA levels in liver and kidney among strains, a similar magni-
tude of induction of PPARa-responsive genes (eg, Cyp4a10) was
observed in both wild type and hPPARa mice. Although levels of
hepatic and renal Acox1 induction were generally higher in wild
type compared with hPPARa mice, the differences were not as
dramatic as one would have anticipated given the nearly
10-fold difference in liver and kidney TCA levels between these
2 strains. Previous reports have shown that basal nuclear levels
of PPARa in the livers of hPPARa mice is about 10-fold greater
than levels of PPARa in the livers of wild type mice (Ramdhan
et al., 2010). Additionally, the inducibility of PPARa is similar in
hPPARa and wild type mice (Cheung et al., 2004). Therefore, the
difference in PPARa protein levels between hPPARa and wild
type mice may be contributing to the observed concordance in
the downstream effects on gene expression, in spite of discord-
ance in TCA levels. In addition, we note that tissue levels of TCA
levels alone may not be indicative of the potential to induce
PPARa signaling events, because the total amount of oxidative
metabolites was not different among strains.
It is also noteworthy that the association between PPARa
genotype and TCE-associated hepatomegaly is controversial
and our work provides independent observations that
strengthen one side of the argument. Specifically, Nakajima
et al. (2000) and Ramdhan et al. (2010) (750 mg/kg/day of TCE [i.g.]
for 2 weeks and 2000 ppm of TCE [equivalent to 1600 mg/kg/day]
for 7 days [8 h/day], respectively), reported the increase in liver
to body weight ratio in both wild type and Ppara-null mice. A
third study (Laughter et al., 2004), in which 1500 mg/kg/d of TCE
was administered (i.g.) to mice for 3 weeks, reported that liver
enlargement was observed in wild type and Ppara-null mice;
however, statistical significance was only reached in wild type
mice. In the present study, increased liver to body weight ratio
was observed in both male wild type and Ppara-null mice
exposed to TCE (400 mg/kg/day for 4 weeks). Thus, the liver to
body weight ratio data presented here are consistent with
Nakajima et al. (2000) and Ramdhan et al. (2010), and not with
Laughter et al. (2004). The reasons for these discrepancies are
unknown but may be reflective of inter-laboratory variability,
such as differences in diet.
Nakajima et al. (2000) also reported significant sex differen-
ces in TCE-induced PPARa activation, where male mice were
more sensitive to PPARa induction, and had higher basal levels
of PPARa compared with female mice. However, the authors
also reported that TCE-induced peroxisome proliferation was
similar in both males and females, suggesting that PPARa is not
the only contributor to TCE-induced peroxisome proliferation
(Nakajima et al., 2000). Although male mice are thought to be
more sensitive to hepatic induction of PPARa compared with
female mice following TCE administration, and a higher per-
centage of male mice develop liver tumors after chronic TCE
exposure, both sexes are sensitive to hepatocellular carcinoma
and adenoma development after exposure to TCE
(National Toxicology Program, 1990). Moreover, while TCA indu-
ces peroxisome proliferation in both rats and mice, TCA has
been shown to be tumorigenic in mice, but not rats (DeAngelo
et al., 1997, 2008). Furthermore, TCE-induced mouse liver tumors
have a different pattern of H-ras mutation frequency and/or c-
jun immunoreactivity from those induced by TCA alone or other
peroxisome proliferators (Bull et al., 2002; Fox et al., 1990).
FIG. 7. Expression of Cyp4a10 mRNA following administration of 400 mg/kg (i.g.) TCE. Expression in (A) liver and (B) kidney of mice treated with a single dose of TCE.
Expression of Cyp4a10 mRNA in (C) liver and (D) kidney of mice treated with repeat-dose of TCE (5 days/week, 4 weeks). Box and whisker plots are shown (þ, mean;
line, median; box, inter-quartile range; whiskers, min to max). When box is shown, 4 animals per group were available. Otherwise, there were 3 animals per group.
Symbol (†) denotes a significant difference (p< .05) compared with vehicle-treated group within same strain and sex.
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In this study, the degree of Cyp4a10 and Acox1 induction was
higher in males compared with females. In the liver, there was
an approximate 10-fold increase of Cyp4a10 in male wild type
and hPPARa mice compared with strain-matched female mice.
This was observed in both single and repeat dose studies; thus,
these results are consistent with findings of Nakajima et al.
(2000). This is also consistent with the observation of increased
TCA levels in the livers and kidneys of male mice compared
with female mice. However, the amount of TCA in the liver or
kidney was at most 5-fold higher in males compared with
females. This is in agreement with the existence of a nonlinear
relationship between tissue levels of TCA and PPARa activation
(Yoo et al., 2015a,b).
In summary, these results conclusively demonstrate that
altering PPARa leads to changes in the toxicokinetics of TCE
metabolites. Specifically, hepatic and renal levels of TCA are sig-
nificantly higher in wild type mice compared with Ppara-null
and hPPARa mice after a single- or repeat-dose TCE exposure. A
mechanistic basis for these differences remains to be eluci-
dated. These effects are not likely to be due to changes in the
production of TCA, as our results show that neither hepatic
CYP2E1 expression nor serum levels of TCA differed among the
3 genotypes. Interestingly, despite the differences in TCA levels,
activation of PPARa as measured by Cyp4a10 induction was sim-
ilar in wild type and hPPARa mice, possibly due to differences in
basal PPARa levels. TCE exposure at the level and duration of
our experiment did not elicit much in the way of liver or kidney
toxicity beyond hepatomegaly, even in wild type mice, so the
relative roles of toxicokinetic and toxicodynamic factors
affected by PPARa status in TCE toxicity remains unclear and
requires further study. Future studies of TCE, and other com-
pounds where one or more metabolites is the active toxic moi-
ety, should take into account the possible interactions between
genotype and toxicokinetics by simultaneously measuring
internal markers of both toxicity and metabolite levels, even in
the absence of an a priori hypothesis for how such an interaction
may occur. Otherwise, studies comparing wild type, knockout
or transgenic animals may incorrectly attribute observed differ-
ences in toxicity exclusively to receptor-mediated toxicody-
namic factors, thereby ignoring possible toxicokinetic factors
that affect internal dose.
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